Adial Pharmaceuticals (ADIL) Return on Capital Employed (2018 - 2026)
Adial Pharmaceuticals (ADIL) posted Return on Capital Employed of 292.92% for Q1 2026, down 21.1% sequentially from 241.87% in Q3 2025, and up 4459.0% YoY from 6.43% in Q1 2025.
Adial Pharmaceuticals (ADIL) Return on Capital Employed (2018 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Return on Capital Employed for 9 years, with the latest figure at 292.92% in Q1 2026.
- Quarterly Return on Capital Employed rose 4459.0% year-over-year to 292.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 292.92% (up 4459.0% YoY) and the FY2025 annual result came in at 163.52%, up 546.0% from the prior year.
- Return on Capital Employed retreated to 292.92% in Q1 2026 per ADIL's latest filing, from 241.87% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 98.03% in Q1 2024 and troughed at 353.21% in Q1 2023.
- A 5-year average of 228.67% and a median of 226.12% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 25518 bps in 2024, then tumbled 23947 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 231.58% in 2022, then increased by 18 bps to 190.5% in 2023, then fell by 16 bps to 220.65% in 2024, then dropped by 10 bps to 241.87% in 2025, then declined by 21 bps to 292.92% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 292.92%, 241.87%, and 281.01% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | -521.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -292.92% |
| Sep 30, 2025 | -241.87% |
| Jun 30, 2025 | -281.01% |
| Mar 31, 2025 | -337.51% |
| Dec 31, 2024 | -220.65% |
| Sep 30, 2024 | -197.22% |
| Jun 30, 2024 | -99.26% |
| Mar 31, 2024 | -98.03% |
| Dec 31, 2023 | -190.50% |
| Sep 30, 2023 | -306.86% |
| Jun 30, 2023 | -263.38% |
| Mar 31, 2023 | -353.21% |
| Dec 31, 2022 | -231.58% |
| Sep 30, 2022 | -185.35% |
| Jun 30, 2022 | -154.56% |
| Mar 31, 2022 | -204.81% |
| Dec 31, 2021 | -309.20% |
| Sep 30, 2021 | -229.94% |
| Jun 30, 2021 | -261.83% |
| Mar 31, 2021 | -268.50% |